Ann: Investor Presentation - March 2017, page-20

The good news and the not so good news.
Firstly the good news. You could not have had any more of a bullish corporate overview, I mean these guys are good, They have all the expertise, research, extraction facility and distribution methodology all sorted with cash in the bank and first mover advantage.
They also have the derma products as a secondary revenue stream along with all the billions of dollars emanating from the MM market.
The bad news is who differentiated between MGC Derma and MXC the company that owns 51% of MGC Derma? As far as most were concerned I for one was of the view that 100% of the derma revenue would flow into MXC. I wouldn't mind betting that the other 49% are owned by the same people sitting on the MXC board and their buddies, but then I could be accused of being a conspiratorist! I do have some reservations about management, but on balance I'm going along with it atm. I hear you winnermelon.
That aside MXC I believe own 100% of the MM research, cultivation and supply and this is by far the biggest opportunity